Kobayashi H, Ohishi T, Nishiie H, Kobayashi S, Inoue A, Oka T, Nakamizo N
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Arzneimittelforschung. 1988 Nov;38(11A):1747-9.
The absorption, distribution and excretion of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarb oxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) were studied after repeated doses to rats. The results were summarized as follows: 1. After oral repeated administration once a day for 3 weeks, the radioactivities in blood and tissues increased up to the 14th day, and thereafter they tended to show the steady state. 2. The radioactivity in the tissues at 1 h after last dosing was compared with that at 1 h after single administration. Both tissue distribution patterns were not markedly different, but the concentrations in the liver, testicles, skin and descending aorta significantly increased, showing approximately the 2-fold radioactivities. 3. The radioactivities were excreted in the urine (6%) and feces (88%). The excretion of radioactivity in urine and feces did not change markedly during the repeated administration period.
对大鼠重复给药后,研究了(±)-(R*)-2,6-二甲基-4-(间硝基苯基)-1,4-二氢吡啶-3,5-二羧酸(R*)-1-苄基-3-哌啶酯甲酯盐酸盐(盐酸贝尼地平,KW-3049)的吸收、分布和排泄情况。结果总结如下:1. 每天口服给药一次,连续3周,血液和组织中的放射性在第14天达到最高,此后趋于稳定。2. 将末次给药后1小时组织中的放射性与单次给药后1小时的进行比较。两种组织分布模式无明显差异,但肝脏、睾丸、皮肤和降主动脉中的浓度显著升高,放射性约为原来的2倍。3. 放射性通过尿液(6%)和粪便(88%)排泄。在重复给药期间,尿液和粪便中的放射性排泄无明显变化。